4.02
-0.05(-1.23%)
Currency In USD
| Previous Close | 4.07 |
| Open | 4.08 |
| Day High | 4.12 |
| Day Low | 3.97 |
| 52-Week High | 10.48 |
| 52-Week Low | 1.6 |
| Volume | 206,676 |
| Average Volume | 381,701 |
| Market Cap | 147.81M |
| PE | -1.85 |
| EPS | -2.17 |
| Moving Average 50 Days | 4.49 |
| Moving Average 200 Days | 3.07 |
| Change | -0.05 |
If you invested $1000 in Protara Therapeutics, Inc. (TARA) 10 years ago, it would be worth $8.88 as of March 14, 2025 at a share price of $4.02. Whereas If you bought $1000 worth of Protara Therapeutics, Inc. (TARA) shares 5 years ago, it would be worth $165.43 as of March 14, 2025 at a share price of $4.02.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Protara Therapeutics to Present at the TD Cowen 45th Annual Health Care Conference
GlobeNewswire Inc.
Feb 26, 2025 1:00 PM GMT
NEW YORK, Feb. 26, 2025 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced that management will participate in a
Protara Therapeutics to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference
GlobeNewswire Inc.
Feb 05, 2025 1:00 PM GMT
NEW YORK, Feb. 05, 2025 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced that management will participate in a
Protara Highlights Recent Updates and Anticipated 2025 Milestones
GlobeNewswire Inc.
Jan 13, 2025 1:00 PM GMT
Reported positive six-month data from ADVANCED-2 trial of TARA-002 in patients with NMIBC Completed approximately $100 million public offering, extending runway into 2027 Initial data from 12-month evaluable NMIBC patients in ADVANCED-2 trial expecte